IDEAYA Q3: $1.15B Cash, Wider $125.7M Loss, Phase 3 OptimUM-010 Halted
IDYA sits 17% above its 52-week low of $26.81 on elevated volume (1.8× avg).
Summary
IDEAYA ended Q3 with $1.15 billion in cash and a $125.7 million quarterly loss, and disclosed it is closing the Phase 3 OptimUM-010 neoadjuvant darovasertib trial while the mUM NDA sits with the FDA under RTOR.
Key Events · Earnings and Guidance · IDYA
-
Q3 Loss Widens to $125.7 Million
Net loss was $125.7 million ($1.22 per share) versus net income of $119.2 million a year earlier, when the $207.8 million Servier upfront was recognized. Nine-month net loss reached $336.7 million.
-
Phase 3 OptimUM-010 Enrollment Halted
IDEAYA decided to stop enrollment and close the Phase 3 neoadjuvant darovasertib trial due to site activation and enrollment challenges, pivoting to publishing OptimUM-09 data to support guideline inclusion and payer coverage.
-
Cash Covers Roughly Four Years of Burn
$1.15 billion in cash and marketable securities at September 30, 2026 against $256.9 million of nine-month operating cash use; management states funding for at least twelve months from the filing date.
-
Darovasertib mUM NDA Filed Under RTOR
The NDA for the darovasertib combination in metastatic uveal melanoma was submitted to the FDA in Q3 under the Real-Time Oncology Review program, triggering a $2.0 million Novartis milestone payment.
Analysis · IDYA · Life Sciences
The headline numbers were already out via this morning's 8-K, but the 10-Q carries two things the release did not: the decision to stop enrollment and close the Phase 3 OptimUM-010 neoadjuvant darovasertib trial, and the full cash-burn picture. Nine-month operating cash use was $256.9 million against a $336.7 million net loss, so the $1.15 billion balance sheet buys roughly four to five years at the current burn — enough to fund the darovasertib mUM NDA through FDA review and the IDE849 Phase 3 starts without another raise. The trade-off is that dropping a Phase 3 program narrows the neoadjuvant path to guideline inclusion and payer coverage rather than a registrational trial, while R&D keeps climbing (up 46% year over year in Q3 to $121.6 million).
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IDYA was trading at $31.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $26.81 to $42.68. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.